C. Suárez Rodríguez
About
C. Suárez Rodríguez is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research.
According to data from OpenAlex, C. Suárez Rodríguez has authored 29 papers receiving a total of 324 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 10 papers in Cancer Research. Recurrent topics in C. Suárez Rodríguez's work include Renal cell carcinoma treatment (21 papers), Cancer Genomics and Diagnostics (10 papers) and Cancer Immunotherapy and Biomarkers (10 papers). C. Suárez Rodríguez is often cited by papers focused on Renal cell carcinoma treatment (21 papers), Cancer Genomics and Diagnostics (10 papers) and Cancer Immunotherapy and Biomarkers (10 papers). C. Suárez Rodríguez collaborates with scholars based in Spain, United Kingdom and United States. C. Suárez Rodríguez's co-authors include James Larkin, Brian I. Rini, Jorge A. García, Elizabeth R. Plimack, Yu-Ning Wong, James H. Finke, Paul Elson, Dale R. Shepard, Tanya B. Dorff and Patricia Rayman and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.
In The Last Decade
C. Suárez Rodríguez
27 papers receiving 322 citations
Peers
C. Suárez Rodríguez
Niels Viggo Jensen Denmark
Alketa Hamzaj Italy
Konstantin Penkov United States
Viktoria Stühler Germany
Christina Schiff United States
Jahangeer Malik United Kingdom
Daniela Cullurà Italy
Craig Norton United States
Shruti Shally Saggi United States
Giulia Grizzi Italy
Citations per year, relative to C. Suárez Rodríguez C. Suárez Rodríguez (= 1×)
peers
Niels Viggo Jensen
Countries citing papers authored by C. Suárez Rodríguez
Since
Specialization
Citations
This map shows the geographic impact of C. Suárez Rodríguez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Suárez Rodríguez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Suárez Rodríguez more than expected).
Fields of papers citing papers by C. Suárez Rodríguez
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by C. Suárez Rodríguez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Suárez Rodríguez. The network helps show where C. Suárez Rodríguez may publish in the future.
Co-authorship network of co-authors of C. Suárez Rodríguez
This figure shows the co-authorship network connecting the top 25 collaborators of C. Suárez Rodríguez. A scholar is included among the top collaborators of C. Suárez Rodríguez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Suárez Rodríguez. C. Suárez Rodríguez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Frangou, Eleni, Grant D. Stewart, Ian D. Davis, et al.. (2025). LBA93 First results from RAMPART: An international phase III randomised-controlled trial of adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma (RCC) led by MRC CTU at UCL. Annals of Oncology. 36. S1635–S1635.
2.
Heijden, Michiel S. van der, Joshua J. Meeks, Toan Quang Vu, et al.. (2024). LBA5 A randomized phase III trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA). Annals of Oncology. 35. S1271–S1271.
3.
Albigès, Laurence, C. Suárez Rodríguez, Giuseppe Procopio, et al.. (2024). 1717TiP CARE1 pragmatic clinical trial: First line randomised study platform to optimize treatment in patients with metastatic renal cell carcinoma. Annals of Oncology. 35. S1029–S1029.
4.
Pérez‐Valderrama, Begoña, et al.. (2023). SEOM SOGUG clinical guideline for treatment of kidney cancer (2022). Clinical & Translational Oncology. 25(9). 2732–2748.
5.
Navani, Vishal, T.B. Powles, Luís Meza, et al.. (2023). 1893P Immune-related adverse events from contemporary first-line combination therapies in metastatic renal cell carcinoma: Results from the IMDC. Annals of Oncology. 34. S1018–S1019.
6.
Choueiri, Toni K., Tom Powles, Laurence Albigès, et al.. (2022). LBA8 Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313). Annals of Oncology. 33. S1430–S1431.
7.
Mirallas, Oriol, Javier Ros, C. Suárez Rodríguez, et al.. (2022). 126P The HLA I composite score and VHIO immune gene-expression signature (VIGex) as selection tools to explore the tumor microenvironment (TME) in patients (pts) treated with immunotherapy (IT). Annals of Oncology. 33. S595–S595.
8.
McGregor, Bradley A., Daniel M. Geynisman, Mauricio Burotto, et al.. (2021). Efficacy outcomes of nivolumab + cabozantinib versus pembrolizumab + axitinib in patients with advanced renal cell carcinoma (aRCC): Matching-adjusted indirect comparison (MAIC).. Journal of Clinical Oncology. 39(15_suppl). 4578–4578.
9.
Porta, Camillo, Mauricio Burotto, C. Suárez Rodríguez, et al.. (2021). 663P First-line nivolumab + cabozantinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC) in subgroups based on prior nephrectomy in the CheckMate 9ER trial. Annals of Oncology. 32. S688–S689.
10.
Pal, Sumanta K., Laurence Albigès, C. Suárez Rodríguez, et al.. (2021). CONTACT-03: Randomized, open-label phase III study of atezolizumab plus cabozantinib versus cabozantinib monotherapy following progression on/after immune checkpoint inhibitor (ICI) treatment in patients with advanced/metastatic renal cell carcinoma.. Journal of Clinical Oncology. 39(6_suppl). TPS370–TPS370.
11.
Rini, Brian I., Michael B. Atkins, Bernard Escudier, et al.. (2021). Abstract CT188: IMmotion151: updated overall survival (OS) and exploratory analysis of the association of gene expression and clinical outcomes with atezolizumab plus bevacizumab vs sunitinib in patients with locally advanced or metastatic renal cell carcinoma (mRCC). Cancer Research. 81(13_Supplement). CT188–CT188.
12.
Rodríguez, C. Suárez, James Larkin, Poulam M. Patel, et al.. (2021). Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer.. Journal of Clinical Oncology. 39(15_suppl). 4511–4511.
13.
Grande, Enrique, Teresa Alonso Gordoa, Òscar Reig, et al.. (2020). INMUNOSUN-SOGUG trial: A prospective phase II study to assess the efficacy and safety of sunitinib as second-line (2L) treatment in patients (pts) with metastatic renal cell cancer (RCC) who received immunotherapy-based combination upfront.. Journal of Clinical Oncology. 38(15_suppl). 5060–5060.
14.
Rodríguez, C. Suárez, James Larkin, Poulam M. Patel, et al.. (2020). Overall survival results for durvalumab and savolitinib in metastatic papillary renal cancer.. Journal of Clinical Oncology. 38(6_suppl). 619–619.
15.
Procopio, Giuseppe, Aristotelis Bamias, Manuela Schmidinger, et al.. (2019). Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer. 17(3). e526–e533.
16.
Morales‐Barrera, Rafael, C. Suárez Rodríguez, Javier Ros, et al.. (2019). Impact of immune-related adverse events on survival in patients with metastastic urothelial carcinoma treated with immune-checkpoint inhibitors.. Journal of Clinical Oncology. 37(15_suppl). 4531–4531.
17.
Powles, Thomas, David F. McDermott, Brian I. Rini, et al.. (2017). IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC). Annals of Oncology. 28. v624–v624.
18.
Choueiri, Toni K., Camillo Porta, C. Suárez Rodríguez, et al.. (2017). A phase 2 study of investigational TORC1/2 inhibitor TAK-228 and TAK-228 plus investigational PI3Kα-selective inhibitor TAK-117 vs everolimus in adults with advanced or metastatic clear-cell renal cell carcinoma (ccRCC) that has progressed on VEGF-targeted therapy. Annals of Oncology. 28. v328–v328.
19.
Rini, Brian I., Tanya B. Dorff, Paul Elson, et al.. (2016). Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. The Lancet Oncology. 17(9). 1317–1324.
20.
Rodríguez, C. Suárez, et al.. (2016). Incidentes y eventos adversos en la Unidad de Cuidados Paliativos de un hospital de agudos geriátricos. Medicina Paliativa. 24(4). 204–209.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Niels Viggo Jensen Breakdown of academic impact, for papers by Alketa Hamzaj Breakdown of academic impact, for papers by Konstantin Penkov Breakdown of academic impact, for papers by Viktoria Stühler Breakdown of academic impact, for papers by Christina Schiff Breakdown of academic impact, for papers by Jahangeer Malik Breakdown of academic impact, for papers by Daniela Cullurà Breakdown of academic impact, for papers by Craig Norton Breakdown of academic impact, for papers by Shruti Shally Saggi Breakdown of academic impact, for papers by Giulia Grizzi